Cranbury-based PMV Pharmaceuticals Inc., a developer of p53 regulators for cancer treatment, announced it has appointed Dr. Deepika Jalota as senior vice president and head of regulatory affairs.
In this role, Jalota will be responsible for regulatory efforts for PMV’s mutant p53 restoration drug pipeline.
“Deepika’s regulatory leadership and strategy in the oncology space have led to multiple product approvals. Her deep experience brings important insights to our efforts as we develop drugs to rescue the function of mutant p53 proteins to treat cancer,” PMV CEO and President David Mack said.
Prior to joining PMV, Jalota most recently served as vice president, global regulatory strategy head, oncology I at Bayer HealthCare Pharmaceuticals. Before that, she was at Sanofi-Aventis, Forest Laboratories and Proctor and Gamble.
“I am delighted to be part of PMV Pharma’s ground-breaking scientific efforts to help advance the company’s p53 portfolio of product candidates. PMV is advancing a pipeline of promising therapeutics that have the potential to improve the outcomes for patients with cancer. The opportunity to join efforts with a world-class team who is working on such an important class of therapeutics is exceptional”, Jalota said.
